Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Tong Ren Tang Technologies Co ( (HK:1666) ) is now available.
Tong Ren Tang Technologies Co. Ltd. reported that shareholders approved, by a large majority vote at an extraordinary general meeting held in Beijing on 6 February 2026, the appointment of Mr. Siu, Paul Yu Hay as an independent non-executive director of the company’s ninth board session, together with his proposed remuneration and service contract. The same meeting also marked the effective resignation of independent non-executive director Mr. Li Siu Bun, resulting in changes to the composition of the board and its committees, a move that signals a refreshed governance structure and may influence the company’s oversight and strategic direction, with more than half of the issued share capital represented at the meeting and all directors attending in person or electronically.
The most recent analyst rating on (HK:1666) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Tong Ren Tang Technologies Co stock, see the HK:1666 Stock Forecast page.
More about Tong Ren Tang Technologies Co
Tong Ren Tang Technologies Co. Ltd. is a PRC-incorporated joint stock company listed in Hong Kong, operating in the pharmaceutical and traditional Chinese medicine sector. It manufactures and sells Chinese patent medicines and related health products, serving both domestic and overseas markets through its role within the Tong Ren Tang group’s broader healthcare and wellness business.
Average Trading Volume: 1,091,243
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.46B
For a thorough assessment of 1666 stock, go to TipRanks’ Stock Analysis page.